Open-label, Multicenter, Observational (Non-interventional) Study of Efficacy and Tolerability of Amtolmetin GuAcil in Subjects With Knee osTeoArthrosis With Dyspepsia. (AGATA)

This study is conducted to study the efficacy and safety of Niselat in patients with osteoarthritis.

Start Date01 Feb 2015

Sponsor / Collaborator

Dr. Reddy's Laboratories Ltd. (Russia)

100 Clinical Results associated with Amtolmetin Guacil

100 Translational Medicine associated with Amtolmetin Guacil

100 Patents (Medical) associated with Amtolmetin Guacil

Literatures (Medical) associated with Amtolmetin Guacil

01 Dec 2022·Annals of Translational Medicine

Comparison of cardiorenal safety of nonsteroidal anti-inflammatory drugs in the treatment of arthritis: a network meta-analysis

Article

Author: Li, Xinlu ; Wang, Kunling

BackgroundArthritis includes osteoarthritis (OA), rheumatoid arthritis (RA), and other arthritis-related disorders. Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used drugs for the treatment of arthritis. However, there remains a concern that some currently used NSAIDs may increase the risk of cardiorenal adverse events in patients with arthritis. Although it has been established that some NSAIDs are associated with a higher risk of cardiovascular and renal events, their safety varies widely. To provide insight into drug use, this study systematically assessed and compared the incidence of cardiovascular and renal events in different NSAIDs by using Bayesian meta-analysis.MethodsThe PubMed, Cochrane Library, and Embase databases were searched for randomized controlled trials (RCTs) on NSAIDs. Databases were searched from the inception to April 25, 2022. Two investigators independently screened articles according to the Population, Intervention, Comparator, Outcomes, Study design (PICOS) principle, extracted data, and assessed the quality of articles using Cochrane Risk of Bias assessing tools. R software (version 4.1.3) was used for network meta-analysis (NMA).ResultsThe analysis ultimately included 20 articles with a total of 144,957 patients and 13 interventions. The risk of bias in the included articles was generally moderate. Ibuprofen was associated with the highest incidence of hypertension outcomes [comparing with placebo OR (95% CI): 3.24 (1.71, 5.82)], rofecoxib with the highest incidence of renal events [comparing with placebo OR (95% CI): 4.46 (1.49, 14.73)], ibuprofen with the highest incidence of cardiovascular events [comparing with placebo OR (95% CI): 2.39 (0.82, 8.06), and naproxen with the highest incidence of edema [comparing with placebo OR (95% CI): 2.31 (1.16, 4.47)].ConclusionsThe NMA results showed that amtolmetin guacil was relatively safer, but it needs further investigation. Rofecoxib was associated with a higher incidence of cardiorenal adverse events, ibuprofen with a higher incidence of cardiovascular events and hypertension, and naproxen with a higher incidence of renal events and edema. Clinicians should weigh the efficacy of NSAIDs against renal and cardiovascular toxicity when prescribing NSAIDs for the treatment of arthritis.

22 Mar 2016·Arthritis

Amtolmetin: A Reappraisal of NSAID with Gastroprotection

Article

Author: Sharma, Akhilesh ; Shoeb, Ahsan ; Moodahadu, Latha Subramanya ; Gandhi, Arul ; Akku, Shyam ; Garg, Amit

Aim. To assess the gastrosparing effect of amtolmetin guacyl (AMG) against other nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with osteo-/rheumatoid arthritis. Methods. A literature search was done in the electronic databases (PubMed, Google Scholar, Embase, and Scopus) with key words “amtolmetin guacyl”, “amtolmetin”, and “arthritis”; filters were applied to obtain publications between 01-Jan-1985 and 01-Oct-2015, which were “clinical trials” in osteo-/rheumatoid arthritis patients and in “English language.” Studies were assessed using the Jadad criteria and trials with score ≥ 3 were included in the analysis to compare the safety and efficacy of AMG against other NSAIDs. Results. Search yielded 19 publications of which 3 were included for analysis. Baseline characteristics of patients were comparable between the AMG group and other NSAIDs (diclofenac, celecoxib, and piroxicam) groups in all trials. Efficacy of AMG was similar to the other NSAIDs compared in the trials. The number of adverse events (AEs) reported was similar between both the groups; however, severe AEs reported were significantly lower in the AMG group. Of note was the significant lower number of duodenal ulcers after treatment in the AMG group. Conclusions. AMG has efficacy similar to other NSAIDs and a safer gastrointestinal AE profile when compared to the other NSAIDs.

01 Jan 2016·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

A choice of a nonsteroidal anti-inflammatory drug with regard to gastrointestinal and cardiovascular risks

Review

Author: Pakhomova, I G

NSAIDs are effective drugs among analgesics and antiinflammatory drugs used widely in clinical practice. It is important to emphasize that the range of users of NSAIDs in population are patients with chronic disorders of the joints and spine. However,when prescribing NSAIDs one should consider risk factors of side-effects not only from the gastrointestinal tract, but cardiovascular events as well. The potential negative risks of using NSAIDs promote an active research on creation of ne...y medicinal substances which are able to minimize NSAID-induced complications. The use of oxide-nitrogen-associated NSAIDs, in particular amtolmetin guacil1in patients with risk factors of side-effects from the gastrointestinal tract and cardiovascular system seems to be promising.It is noted that amtolmetin guacil has balanced analgesic and anti-inflammatory effects and is well tolerated.

100 Deals associated with Amtolmetin Guacil

External Link

KEGG	Wiki	ATC	Drug Bank
D07453	Amtolmetin Guacil	M01AB03 M02AA21	DB16088

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	IT	Sigma-Tau Industrie Farmaceutiche Riunite SpA	01 Jul 1995
Pain	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2019	Not Applicable	Osteoarthritis \| Rheumatoid Arthritis \| Ankylosing Spondylitis	-	Amtolmetin guacil 600-1800 mg/day	(ezdvmyjahd) = The development or worsening of arterial hypertension, as well as other cardiovascular complications, was not observed ndxwmdmwio (rnaqqbrsrl ) View more	Positive	12 Jun 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Amtolmetin Guacil

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation